The three-day China (Suzhou) Innovative Drug Medical Conference (CMAC) concluded successfully at the Suzhou International Expo Center from March 18th to 20th. Under the theme of "Converging Medical Insights, Uniting Innovation," the event brought together over 3,000 industry leaders, clinical experts, and regulatory representatives. The opening ceremony on the first day was fully packed, reflecting the pharmaceutical industry’s high expectations and enthusiasm for innovative R&D.
Glodom was honored to participate in this year’s CMAC conference. As a professional language service provider with over two decades of expertise in the life sciences sector, we showcased our full-chain AI language intelligent solutions at Booth B28 through immersive interactive experiences, case demonstrations, and technical exchanges. Leveraging AI technology and our ISO 13485-compliant multilingual service system for medical devices, we highlighted end-to-end language support—from intelligent medical document translation and standardized terminology management to multilingual compliance review. The booth attracted numerous pharmaceutical representatives for in-depth discussions. Multiple enterprises explored how AI technology enhances document efficiency and optimizes multilingual document quality, underscoring the industry’s keen focus on intelligent solutions empowering pharmaceutical innovation.
Against the backdrop of accelerating globalization, Glodom remains grounded in international quality management standards. By strictly adhering to ISO 13485 requirements, our language service system not only ensures precise terminology management in the medical device field but also achieves full-process risk control and traceability in multilingual compliance reviews. This capability provides pharmaceutical and medical device companies with seamless solutions to meet global regulatory demands—from document translation to submission audits—helping clients overcome language barriers and accelerate product market access worldwide.
As the official interpretation service provider for the conference, Glodom also delivered high-quality simultaneous interpretation for core forums. With extensive experience and technical expertise in pharmaceutical translation, we provided attendees with a conference experience that was "clear, comprehensible, and interactive," ensuring efficient cross-border communication.
This year’s CMAC conference featured three parallel forums diving into the latest advancements and future directions across sectors. The Drug Regulation & Innovation Forum focused on regulatory reforms to accelerate China’s leadership in launching innovative drugs. The Medical Affairs Forum prioritized cognitive breakthroughs to maximize medical value, while the Device & IVD Forum centered on policy interpretations to steer high-quality industry development. Of particular note was the "Dialogue with China’s R&D Leaders" session, where pioneering enterprises exchanged ideas on long-term R&D strategies and ecosystem collaboration, injecting fresh momentum into drug innovation.
Through CMAC’s industry innovation platform, we witnessed the remarkable evolution of China’s pharmaceutical innovation ecosystem—from conceptual debates a decade ago to today’s value consensus, and from isolated technological breakthroughs to cross-industry synergy. CMAC has consistently prioritized patient-centric care and clinical value, driving deeper integration of medical innovation and practice. Moving forward, Glodom will deepen collaborations with CMAC and other authoritative platforms, advancing China’s pharmaceutical innovation from "catching up" to "leading the way," and joining hands with industry peers to chart a new vision for high-quality development in biopharma.
